It is essential to consult with a qualified healthcare provider or physician for any inquiries related to a medical condition, treatment, or before initiating any new healthcare routines
In addition, SGLT-2 inhibitors have shown benefit in patients with both HFrEF and HFpEF independently of diabetes status, which opens exciting possibilities for the use of these therapies in patients at risk for or with established CV or kidney disease without T2D
Eligibility is checked at your clinical evaluation visit
These factors highlight the need for careful consideration and monitoring when prescribing these medications, especially in individuals at risk of eating disorders (Bartel et al., 2024)
Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, Xu G, Pu Y, Zhu Z, Xu A, et al: Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism
We advise waiting at least 30 minutes after taking your dose before eating or drinking anything
